Recent evidence elucidates the intricate crosstalk between ER and HER2 signaling pathways, supporting dual blockade strategies in breast cancer co-expressing hormone receptors and HER2 [24, 25]. This evidence concerns the gene NR4A1 and breast carcinoma.